BioCryst Pharma (BCRX) Appoints Vincent Milano to its Board

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has appointed hereditary angioedema (HAE) and rare disease industry leader, Vincent Milano, to its board of directors.

Mr. Milano currently serves as chief executive officer of Idera Pharmaceuticals, Inc., and previously served as chairman, president and chief executive officer of ViroPharma, which successfully developed and launched Cinryze for the treatment of HAE in the United States and Europe, prior to its acquisition by Shire in 2014. Prior to joining ViroPharma in 1996, he served as a senior manager at KPMG LLP, an independent registered public accounting firm.

“I have seen first-hand how valuable innovation is for HAE and other rare disease patients and I am excited to join alongside Jon and the board as BioCryst continues to leverage its industry-leading combination of scientific and commercial rare disease expertise to deliver its prolific pipeline of novel oral medicines for rare diseases to patients,” Milano said.

“As we got to know Vin through our discussions with Idera several years ago, we were incredibly impressed with his deep and successful rare disease and HAE experience and we are delighted to add his expertise to the BioCryst board as the company brings ORLADEYO® (berotralstat) to HAE patients around the world and advances its pipeline programs, like BCX9930,” said Robert Ingram, chairman of BioCryst.

Mr. Milano currently serves on the boards of directors of Idera Pharmaceuticals, Aclaris Therapeutics and VenatoRx Pharmaceuticals, and is the chairman of the board for Life Science Cares Philadelphia. He received his Bachelor of Science degree in accounting from Rider College.

You May Also Be Interested In

• BioCryst names David Jenkins as chief scientific officer
• SST VI to acquire SSGT III in all-stock merger valued at $1.2B
• INmune Bio publishes preclinical study on XPro1595 and brain injury